NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
BörsenkürzelNPCE
Name des UnternehmensNeuropace Inc
IPO-datumApr 22, 2021
CEOMr. Joel D. Becker
Anzahl der mitarbeiter184
WertpapierartOrdinary Share
GeschäftsjahresendeApr 22
Addresse455 N. Bernardo Avenue
StadtMOUNTAIN VIEW
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl94043
Telefon16502372700
Websitehttps://www.neuropace.com/
BörsenkürzelNPCE
IPO-datumApr 22, 2021
CEOMr. Joel D. Becker
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten